University of British Columbia
Curriculum Vitae for Faculty Members
Date:
Initial:
FIRST NAME:
1.
SURNAME :
Kollmannsberger
2.
DEPARTMENT/SCHOOL:
Medicine / Div. of Medical Oncology
3.
FACULTY:
Medicine
4.
PRESENT RANK:
Clinical Associate Professor
MIDDLE NAME(S):
SINCE:
February 02th 2009
CK
Christian
Kurt
1/2006
5. POST-SECONDARY EDUCATION
University or Institution
Degree
Subject Area
Dates
University of British Columbia
Clinical Associate
Professor of Medicine
Dept. of Medicine
January 2006
– present
British Columbia Cancer Agency
Medical Oncologist
Div. of Medical Oncology
January 2004
- present
University of Tuebingen
Associate Professor
Hematology / Medical Oncology
2003-2004
University of Tuebingen
Hematologist / Medical
Oncologist
Hematology / Oncology
2001-2003
University of Tuebingen, Germany
Internist
Internal Medicine
1996-2001
University of Munich, Germany
-
Internal Medicine
1995-1996
University of Freiburg, Germany
-
Internal Medicine
1993-1995
University of Washington, Seattle
-
Clinical elective in Gastroenterology
1992
McGill University, Montréal
-
Clinical elective in Cardiology
1992
University of Munich
MD
Medicine
1989-1993
University of Regensburg,
Germany
-
Medicine
1986-1988
1
Special Professional Qualifications
Royal College of Physicians and Surgeons of Canada Academic Certification 2008
Certification - German Board of Hematology / Oncology 2003
Certification - German Board of Internal Medicine 2001
Certification - European Society of Medical Oncology 2000
Medical Council of Canada Evaluating Examination 1996
United States Medical Licensure Examination Step I, II, III 1995 / 1996
Final Medical Examination 1993
6. EMPLOYMENT RECORD
Prior
University, Company or Organization
Rank or title
Dates
University of Tuebingen, Germany
Dept. of Internal Medicine
Associate Professor (“Privatdozent”)
June 23rd 2003 - present
University of Tuebingen, Germany
Dept. of Internal Medicine
Fellow Hematology / Medical
Oncology
2001-2003
University of Tuebingen, Germany
Dept. of Internal Medicine
Resident
1997-2000
University of Munich, Germany
Dept. of Internal Medicine
Resident
1995-1996
University of Freiburg, Germany
Dept. of Internal Medicine
Resident
1993-1995
Present
University, Company or Organization
Rank or title
Dates
University of British Columbia /
Clinical Associate Professor
January 1st 2006 – present
British Columbia Cancer Agency
Medical Oncologist
January 26th 2004 - present
7. LEAVES OF ABSENCE
2
University, Company Or Organization at
which Leave was taken
Type of Leave
Dates
8. TEACHING
(a) Areas of special interest and accomplishments
(b) Courses Taught at the University of Tuebingen, Germany / University of British Columbia:
Year
Session
Course Number
Scheduled
Class
Hours
Taught
Hours
Size
Lecture
Tutorials
2001 2003
Physical examination
2 per week
8
X
2001 2003
Clinical-oncological
case conference
2 per week
8-15
X
2001 2003
Surgical-oncological
case conference
2 per week
8-15
X
2001 2003
Clinical Oncology
1 per week
10
X
2004
Academic Half-day
1.5 hours
10
x
2005
Academic Half-day
1.5 hours
10
x
2006
Academic Half-day
1.5 hours
10
x
2006
Clinical skills course
8 hours
2
2007
Academic half day
1.5 hours
10
2007
Clinical skills course
8 hours
2
Labs
Other
x
x
x
3
2008
Clinical skills course
8 hours
2
2008
Academic half day
1.5 hours
10
x
x
(c) Graduate Students supervised at the University of Tuebingen, Germany:
Student Name
Program Type
Year
Start
Principal Supervisor
Co-Supervisors
Finish
Karin Oechsle
Medicine (MD)
1999
2001
Prof. C. Bokemeyer MD
Dr. C. Kollmannsberger
Barbara Schuto
Medicine (MD)
2002
2004
Prof. C. Bokemeyer MD
Dr. C. Kollmannsberger
(d) Continuing Education Activities
(e) Visiting Lecturer (indicate university/organization and dates)
(f) Other
-
9. SCHOLARLY AND PROFESSIONAL ACTIVITIES
(a) Areas of special interest and accomplishments
Evaluation of prognostic factors and development of new therapeutic strategies in patients with urological and
gastrointestinal malignancies, particularly germ cell, renal cell and gastric cancer.
Development of adjuvant and palliative therapeutic strategies in patients with upper GI malignancies.
Investigation of late toxicity and secondary neoplasms in patients treated for Hodgkin´s disease or germ-cell
tumors.
Development of new anti-tumor agents in patients with solid tumors, particularly germ-cell cancer, renal cell
cancer and GI malignancies.
4
(b)+(c) Research or equivalent grants/contracts (indicate under COMP whether grants were obtained
competitively (C) or non-competitively (NC))
Granting
Principal
Subject
COMP
$ Per
Year
Bristol-Myers
Squibb, Germany
Paclitaxel in patients with
metastatic gastric cancer
NC
32 000
1997
2001
C. Bokemeyer
Fortune program
- University of
Tuebingen
Molecular
prognostic
factors in patients with
refractory germ cell cancer
C
22 000
2000
2001
C. Kollmannsberger
Ribosepharm,
Germany
Bendamustin in patients
with refractory germ cell
cancer
NC
4 000
2001
2002
C. Kollmannsberger
C. Bokemeyer
Aventis Pharma,
Irinotecan in patients with
refractory germ cell cancer
NC
8 000
2001
2002
C. Kollmannsberger
C. Bokemeyer
Fortune program
- University of
Tuebingen
Meta-analysis
on
carboplatin in seminoma
C
22 000
2001
2002
C. Kollmannsberger
C. Bokemeyer
Bristol-Myers
Squibb, Germany
Paclitaxel
for
adjuvant
treatment of gastric cancer
NC
27 000
2001
2003
C. Kollmannsberger
C. Bokemeyer
Lilly, Germany
Gemcitabine/Oxaliplatin
testis cancer
NC
16 000
2002
2003
C. Kollmannsberger
C. Bokemeyer
AKF program University of
Tuebingen
Paclitaxel
for
adjuvant
treatment of gastric cancer
C
20 000
2001
2003
C. Kollmannsberger
C. Bokemeyer
AKF program University of
Tuebingen
Molecular
prognostic
factors in gastric cancer
C
2002
2003
C. Kollmannsberger
Amgen, Germany
Darbepoetin
cancer
testis
NC
20 000
2003
2006
C. Bokemeyer
Pfitzer Canada
SU011248 in refractory
Germ cell cancer
NC
340 000
2006
2008
C. Kollmannsberger
Agency
Germany
in
in
23 000
Year
Investigator
Co-Investigator(s)
C.
Kollmannsberger
C. Bokemeyer
Mayer F.
W. Budach
C. Bokemeyer
Mayer F.
C.
Kollmannsberger
C. Bokemeyer
M. Moore
E. Winquist
T. Chen
L. Wood
P. Czaykowski
5
(d) Invited Presentations
1. VIII Erlanger Clinical Conference on Lung Diseases, Erlangen, Germany 1997: „Advances in Pneumology:
High-dose chemotherapy with autologous stem cell support in small cell lung cancer.
2. Grand Rounds, Dept. Of Medical Oncology, University of Essen, Germany 1998. "Treatment associated
leukemia”
3. UICC Symposium on Testicular Cancer, Tuebingen, Germany 1999. „Secondary malignancies".
4. Annual Meeting of the German Society of Hematology/Medical Oncology, 1999. "Treatment-related
malignancies following treatment of germ cell cancer
5. Post-ASCO Meeting for Community Oncologists, Muenchen, 1999: “Advances in the treatment of gastric
cancer”
6. Teaching Course “Clinical Oncology” for Residents and Fellows, Frankfurt 2000 (supported by the German
Cancer Society). "Soft-tissue and bone sarcomas".
7. Teaching Course “Clinical Oncology” for Residents and Fellows, Frankfurt, Germany 2001 (supported by the
German Cancer Society). "Standards and current developments in the treatment of upper gastrointestinal
malignancies“
8. Annual Meeting of the German Society of Hematology/Medical Oncology 2001. "Therapy-related
myelodysplastic syndrome and leukemia following chemotherapy treatment of patients with potentially curable
malignancies."
9. Post-ASCO Meeting for Community Oncologists, Munich, Germany 2001: "Advances in the treatment of
esophageal and gastric cancer“.
10. Teaching Course “Clinical Oncology” for Residents and Fellows, Stuttgart, Germany 2002 (supported by the
German Cancer Society)."Advances in the treatment of upper gastrointestinal malignancies”
11. Grand Rounds, Department of Surgery, University of Munich, Germany, 2002: Advances in the Adjuvant
Treatment of Gastric Cancer.
12. Annual Meeting of German Community Oncologists Group, Garmisch-Partenkirchen, Germany 2003:
“Chemotherapy of Gastric Cancer”.
13. Annual Meeting of the German Society of Hematology / Medical Oncology, 2003: “Late toxicity following
chemotherapy of testicular cancer”.
14. MASCC/ISOO 15th. International Symposium on Supportive Care in Cancer, Berlin, Germany 2003. “Therapyrelated neoplasms after chemotherapy and/or radiation therapy in patients with potentially curable
malignancies”.
15. Conference on Molecular Targeted Therapy of Cancer, Stuttgart, Germany 2003: “Targeting EGFR: Small
Molecule Tyrosine Kinase Inhibitors - Preclinical studies”.
16. Second International Conference on Germ Cell Tumors, Ravenna., Italy: “Prognostic and Predictive Factors in
Germ Cell Cancer”.
17. 26th Congress of the German Cancer Society, Berlin, Germany 2004 “Anti-EGFR-Concepts: Preclinical and
Clinical Studies”.
18. 26th Congress of the German Cancer Society, Berlin, Germany 2004: “Adjuvant Therapy of Gastric Cancer”.
19. Annual Meeting of the British Columbia Cancer Agency, Vancouver 2004. “Advances in the chemotherapy of
upper gastrointestinal malignancies”.
20. Annual Community Oncologists' Meeting, Vancouver 2004: “Advances in the Chemotherapy of Bladder
Cancer”.
21. Teaching Course “Clinical Oncology” for Residents and Fellows, Berlin, Germany 2004 (supported by the
German Cancer Society)."Treatment of upper gastrointestinal malignancies”
6
22. Annual Meeting of the German / Swiss / Austrian Societies of Hematology/Medical Oncology, Hannover,
Germany 2005: “ Advances in the treatment of hormone-refractory prostate cancer”.
23. Atlantic Canada Oncology Meeting, Prince Edward Island June 2006: “Advances in the treatment of testis
cancer”.
24. The Canadian Association of Pharmacy in Oncology - National Oncology Pharmacy Symposium October
2006: “Advances in the treatment of renal cell carcinoma”.
25. Saskatoon Cancer Centre Grand Rounds, December 2006: “Novel treatments in renal cell carcinoma”
26. Regina Cancer Centre Grand Rounds, February 2007: “Renal cell carcinoma – new strategies”.
27. Radiation Oncology Grand Rounds, Vancouver December 2006: “VEGF-Receptor blockade – A Breakthrough
in the treatment of Advanced renal cell carcinoma ?”
28. Cancer Care Manitoba Grand Rounds, June 2007: “Renal cell carcinoma – novel therapies”.
29. Canadian Association of Nurses in Oncology Annual Meeting, Vancouver October 2007: “New agents in renal
cancer: novel drugs – novel side effects”.
30. Canadian Association of Nurses in Oncology Annual Meeting, Vancouver October 2007: “Treatment of
hormone-refractory prostate cancer: chemotherapy or no chemotherapy”.
31. Canadian Urologic Oncology Group Retreat, Vancouver October 2007: “Targeted Therapies for RCC”.
32. Canadian Urologic Oncology Group Retreat, Vancouver October 2007: “Cost & Benefit of New Drugs:
Worthwhile? Negligible? Unaffordable?”
33. Issues and Controversies in Prostate Care, Cancun January 2008: “What is the biology of renal cell
carcinoma”
34. Issues and Controversies in Prostate Care, Cancun January 2008: “The VEGF pathway in RCC”
35. Issues and Controversies in Prostate Care, Cancun January 2008: “Management of toxicity of renal cell
carcinoma treatment”.
36. European Society of Medical Oncology International Symposium on Testicular Cancer, Munich May 2008:
“Treatment of malignant non-germ cell transformation”
37. European Society of Medical Oncology International Symposium on Testicular Cancer, Munich May 2008:
“New treatment options”
38. Canadian Urology Association Annual Meeting, Edmonton June 2008: “Chemotherapy for stage I
nonseminomatous germ cell cancer”
39. 28th Annual Canadian Cancer Registry Professionals Workshop (CCRPW) October 2008: “Genitourinary
tumors”
40. Issues and Controversies in Prostate Care, Cancun January 2009: “Adjuvant and neoadjuvant chemotherapy
for high risk localized prostate cancer”
41. Issues and Controversies in Prostate Care, Cancun January 2009: “What is the Rationale for Multimodal
Therapy? A Biological Perspective”
7
42. American Society of Clinical Oncology Genitourinary Symposium Orlando February 2009: “Testicular Cancer:
Second line therapy and beyond”
(e) Other Presentations (Oral presentations only)
1. Annual Meeting of the German Society of Hematology/Medical Oncology 1997. Analysis of risk factors for
cisplatin-induced ototoxicity in patients with testicular cancer. Published in: Br J Cancer, 77: 1355-1362,
1997.
2. 23rd Congress of the European Society of Medical Oncology, Athens., Greece 1998: "FDG-PET for the
evaluation of high-dose chemotherapy (HD-CTX) in patients with metastatic germ cell tumors (GCT)."
Published in: Cancer, 94: 2353-2362, 1998.
3. 23rd Congress of the European Society of Medical Oncology, Athens., Greece 1998: "A phase II trial of
paclitaxel, cisplatin, and weekly 24h infusion of 5-fluorouracil (5-FU) / folinic acid in patients (pts) with
advanced gastric cancer." Published in: Br J Cancer, 83: 458-462, 1998.
4. 34th Annual Meeting of the American Society of Clinical Oncology, Los Angeles., USA 1998: "Secondary
acute myeloid leukemia (S-AML) or myelodysplastic syndrome (S-MDS) following high-dose etoposide (>/= 2
g/m) containing chemotherapy in 302 patients with germ cell tumors (GCT)." Published in: J Clin Oncol, 16:
3386-3391, 1998.
5. 35th Annual Meeting of the American Society of Clinical Oncology, Atlanta, USA 1999: First-line high-dose
chemotherapy (HD-CT) +/- radiation therapy (RTX) in patients (pts) with CNS metastases of nonseminomatous germ cell tumors (GCT). Published in: Ann Oncol, 11: 553-559, 1999.
6. Annual Meeting of the German Society of Hematology/Medical Oncology 1999: "First-line high-dose
chemotherapy with autologous stem cell support versus standard BEP/VIP in patients with advanced germ
cell cancer" Published in: J Clin Oncol, 17: 3450-3456, 1999.
7. 25th Congress of the European Society of Medical Oncology, Hamburg, Germany. "Reduction of skin toxicity
of pegylated liposomal doxorubicin (PLD) by concomitant administration of dexamethasone (DEX) and
pyridoxine (PYR) in patients (pts) with antracycline-sensitive malignancies - a phase I/II trial." Published in:
Ann Oncol, 11 (Suppl. 4): 136-(abstract 623P), 2000.
8. 36th Annual Meeting of the American Society of Clinical Oncology, New Orleans, USA 2000: A phase II
study of paclitaxel, weekly 24-hour continuous infusion (CI) of 5-fluorouracil / folinic acid (FA) and cisplatin in
patients (pts) with advanced gastric cancer. Published in: Br J Cancer, 83: 458-462, 2000.
9. Annual Meeting of the German Society of Hematology/Medical Oncology 2000: "[18F]-fluorodeoxyglucose
(FDG) positron emission tomography (PET) for the early prediction of response to high-dose chemotherapy
(HD-CT) in patients (pts) with metastatic germ cell cancer." Published in: Br J Cancer, 86: 506-511, 2000.
10. 37th Annual Meeting of the American Society of Clinical Oncology, San Francisco., USA 2001: "Oxaliplatin in
patients (pts) with cisplatin-refractory germ cell cancer (GCT)." Published in: J Clin Oncol, 20: 2031-2037,
2001.
11. Annual Meeting of the German Society of Hematology/Medical Oncology 2001: "Lack of overexpression of
the EGF receptor family in refractory germ cell cancer (GCT)." Published in: Cancer, 95: 301-308, 2001.
12. Annual Meeting of the German Society of Hematology/Medical Oncology 2001: "Oxaliplatin (OX) in patients
(pts) with relapsed or cisplatin refractory germ cell cancer (GCT). Final results of a German Testicular
8
Cancer Study Group investigation." Published in: J Clin Oncol, 20: 2031-2037, 2001.
13. 38th Annual Meeting of the American Society of Clinical Oncology, Orlando, USA 2002: Outcome of patients
(pts) with "poor prognosis" germ cell cancer (GCT) relapsing after primary high-dose chemotherapy plus
stem cell support (pHD/PBSCT). Published in: Eur J Cancer, 39: 775-782, 2002.
14. Annual Meeting of the German Society of Hematology/Medical Oncology 2002: Adjuvant radiochemotherapy
(RTx/CTx) using 5-FU/Folinnic acid (FA)/Cisplatin (CDDP)/Paclitaxel (P) and radiation in patients (pts) with
completely (R0) resected high-risk gastric cancer (UICC stages II-IV (M0)). Published in: Onkologie, 25
(Sonderheft 4): 49-(abstract 169), 2002.
15. Annual Meeting of the German Society of Hematology/Medical Oncology 2003: Combination chemotherapy
with gemcitabine plus oxaliplatin in patients with refractory germ cell cancer: a phase II study of the German
Testicular Cancer Study Group (GTCSG). Published in: J Clin Oncol, 22: 108-114, 2003.
16. Annual Meeting of the German Society of Hematology/Medical Oncology 2003: Single agent carboplatin
versus cisplatin-based combination chemotherapy in patients with advanced seminoma: a meta-analysis of
prospective European trials. Published in: Br J Cancer 683-687, 2003.
17. Annual Meeting of the German Society of Hematology/Medical Oncology 2003: Adjuvant radiochemotherapy
using 5-FU/Folinic acid/cisplatin +/- Paclitaxel and radiation in patients with completely (R0) resected highrisk gastric cancer (UICC stages II-IV (M0): A phase II study of the AIO/ARO/ACO. Published in: Ann Oncol
16: 1326-1333, 2005.
(f) Other
(g) Conference Participation (Organizer, Keynote Speaker, etc.)
Member of the organizing committee and local organizer of the UICC-Meeting on Testicular Cancer 1999.
Member and secretary of the European Consensus Conference on the treatment of testicular cancer 2002.
Speaker, International Conference on Supportive Care in Cancer 2003
Speaker, International Conference on Germ Cell Cancer 2003
Secretary of the German Cancer Congress of the German Society of Cancer 2004
Speaker, Congress of the German Cancer Society 2004
Speaker, Atlantic Canada Oncology Meeting 2006
Member of the European-Canadian Consensus Conference on the Treatment of Testicular Cancer 2006
Member of the organizing committee, First Canadian Consensus Conference on Testicular Cancer 2007
Member of the organizing committee, First Canadian Kidney Cancer Forum, January 2008
Speaker, Canadian Urology Association Annual Meeting 2008
Member Scientific Committee, 20th EORTC-NCI-AACR Symposium on “Molecular Targets and Cancer
Therapeutics” October 2008
Member of the organizing committee, Second Canadian Kidney Cancer Forum, January 2009
10. SERVICE TO THE UNIVERSITY
(a) Memberships on committees, including offices held and dates
9
The representative of the Dept. of Hematology/Medical Oncology in the Tuebingen University Faculty of Medicine
Committee to develop hospital-wide guidelines for physician working hours in accordance with the European
Community Labor Laws, 2002/2003
Member of the Committee to reorganize and optimize departmental structures and procedures, 1997/1998. Within a
pilot project at Tuebingen University Hospital, the Dept. of Hematology/Medical Oncology was selected by the
Hospital Administration to work in cooperation with an external consulting firm specializing in health care. The
committee analyzed existing organizational structures, various areas of operations, related work processes and
data management. Recommendations for improvement were made and subsequent implementation was
supervised and reviewed.
Member of the Committee involved in the construction of modular clinic wards and for the subsequent relocation of
several Dept. of Hematology/Medical Oncology wards into these modules, 2001-2003. Due to modernization
requirements, the Dept. of Hematology was almost completely renovated between 2001 and 2003 and therefore, in
part temporarily and in part permanently, relocated within the University Hospital complex. In addition, the
committee analyzed existing structures, forecasted future requirements and made recommendations to the
superordinate University Building Development Committee
One of the 3 physicians, chosen to develop standardized chemotherapy treatment protocols and pre-printed
chemotherapy orders for the University of Tuebingen Dept. of Hematology / Oncology, 2001.
Co-Chair, Clinical Research Unit for Genitourinary and Phase I Clinical Trials, BCCA since 6/2004
Head, Scientific Evaluation and Review Committee for Gastrointestinal Malignancies, BCCA since 6/2004
Member, Scientific Evaluation and Review Committee for Genitourinary Malignancies, BCCA since 9/2004
Member, National Cancer Institute of Canada Audit and Monitoring Committee, since 2006
Chairman, National Cancer Institute of Canada Disease oriented Group Testis Cancer since 2007
Co-Chair, National Cancer Institute of Canada Disease oriented Group Esophageal/Gastric Cancer since 2007
Member, National Cancer Institute US Esophago-Gastric Intergroup Task Force Group since 2007
(b) Other service, including dates
Chief Resident / Fellow at the Dept. of Medicine II, University of Tuebingen, Germany 2001-2003
11. SERVICE TO THE COMMUNITY
(a) Memberships on scholarly societies, including offices held and dates
Member of the German College of Physicians since 1993
Member of the German Society of Hematology/Oncology since 1997
Member of the European Society of Medical Oncology since 1998
Member of the Working group “Medical Oncology” of the German Cancer Society since 2001
Member of the American Society of Clinical Oncology since 2004
(b) Memberships on other societies, including offices held and dates
(c) Memberships on scholarly committees, including offices held and dates
Member of the Consensus Group of the German Society of Hematology/Oncology for the development of
10
therapeutic recommendations for the treatment of solid tumors.
Member of the „Abstract Reviewer“ group of the German Society of Hematology/Oncology for the Annual
Meeting 1999.
Member of the organizing committee and local organizer of the UICC-Meeting on Testicular Cancer,
1999.
Member of the Interdisciplinary Work Group „Testicular Cancer“ of the German Cancer Society since
2000.
Member of the „Abstract Reviewer“ group of the German Cancer Society for the Annual Meeting 2002
Member and secretary of the European Consensus Conference on the treatment of testicular cancer
2002/2003
Secretary of the German Cancer Congress 2004 of the German Society of Cancer
Member of the organizing committee, First Canadian Consensus Conference on Testicular Cancer 2007
Member of the organizing committee, First Canadian Kidney Cancer Forum, January 2008
Member of the organizing committee, Second Canadian Kidney Cancer Forum, January 2009
Faculty, American Society of Clinical Oncology Genitourinary Symposium February 2009
Faculty, American Society of Clinical Oncology Annual Meeting May/June 2009
(d) Memberships on other committees, including offices held and dates
Member, NCIC Audit and Monitoring Committee since 2006
Member / Co-Chair, NCIC Disease oriented Group Esophagus/Stomach 4/2007
Member / Chair NCIC Disease oriented Group Testis since 12/2007
(f) Reviewer (journal, agency, etc. including dates)
Annals of Oncology
Journal of Cancer Research And Clinical Oncology
British Journal of Cancer
American Journal of Cancer
Onkologie
Cancer Treatment Reviews
Lancet Oncology
Journal of Clinical Oncology
Nature Clinical Practice Oncology
Current Medical Literature
British Journal of Urology
Expert opinion on Investigational Drugs
(g) External examiner (indicate universities and dates)
(h) Consultant (indicate organization and dates)
-
Joint Oncology Drug Review / Ministry of Health Ontario 2008
11
(i) Other service to the community
12. AWARDS AND DISTINCTIONS
(a) Awards for Teaching (indicate name of award, awarding organizations, date)
(b) Awards for Scholarship (indicate name of award, awarding organizations, date)
(c) Awards for Service (indicate name of award, awarding organizations, date)
(d) Other Awards
“Best abstract“: Annual meeting of the German Society of Hematology/Oncology 2001
13. OTHER RELEVANT INFORMATION (Maximum One Page)
12
University of British Columbia
Publications Record
Date:
Initial:
FIRST NAME:
1.
SURNAME: Kollmannsberger
MIDDLE NAME(S):
June 6th 2008
CK
Christian
Kurt
Publications
01. Refereed Publications
(a) Journals
1. Bokemeyer C, Lampe CS, Clemens MR, Hartmann JT, Quietzsch D, Forkmann L,
Kollmannsberger C, and Kanz L: A phase II trial of paclitaxel and weekly 24 h infusion of 5-fluorouracil/folinic
acid in patients with advanced gastric cancer. Anticancer Drugs 8: 396-399, 1997.
2. Bokemeyer C, Berger CC, Hartmann JT, Kollmannsberger C, Schmoll HJ, Kuczyk MA, and Kanz L: Analysis
of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer. Br J Cancer 77: 1355-1362,
1998.
3. Hartmann JT, Harstrick A, Daikeler T, Kollmannsberger C, Muller C, Seeber S, Kanz L, and Bokemeyer C:
Phase II study of continuous 120 h infusion of mitomycin C as salvage chemotherapy in patients with
progressive or rapidly recurrent colorectal cancer. Anticancer Drugs 9: 427-431, 1998.
4. Kollmannsberger C, Peters HD, and Fink U: Chemotherapy in advanced pancreatic adenocarcinoma.
Cancer Treat.Rev. 24: 133-156, 1998.
5. Kollmannsberger C, Hartmann JT, Kanz L, and Bokemeyer C: Risk of secondary myeloid leukemia and
myelodysplastic syndrome following standard-dose chemotherapy or high-dose chemotherapy with stem cell
support in patients with potentially curable malignancies. J Cancer Res Clin Oncol 124: 207-214, 1998.
*
6. Kollmannsberger C, Beyer J, Droz JP, Harstrick A, Hartmann JT, Biron P, Flechon A, Schoffski P, Kuczyk
M, Schmoll HJ, Kanz L, and Bokemeyer C: Secondary leukemia following high cumulative doses of etoposide
in patients treated for advanced germ cell tumors. J Clin Oncol 16: 3386-3391, 1998.
7. Bokemeyer C, Kollmannsberger C, Meisner C, Harstrick A, Beyer J, Metzner B, Hartmann JT, Schmoll HJ,
Einhorn L, Kanz L, and Nichols C: First-line high-dose chemotherapy compared with standard-dose PEB/VIP
chemotherapy in patients with advanced germ cell tumors: A multivariate and matched-pair analysis. J Clin
Oncol 17: 3450-3456, 1999.
8. Bokemeyer C, Kollmannsberger C, Harstrick A, Beyer J, Gerl A, Casper J, Metzner B, Hartmann JT,
Schmoll HJ, and Kanz L: Treatment of patients with cisplatin-refractory testicular germ-cell cancer. German
Testicular Cancer Study Group (GTCSG). Int J Cancer 83: 848-851, 1999.
9. Hartmann JT, Albrecht C, Schmoll HJ, Kuczyk MA, Kollmannsberger C, and Bokemeyer C: Long-term
effects on sexual function and fertility after treatment of testicular cancer. Br J Cancer 80: 801-807, 1999.
13
10. Hartmann JT, Kollmannsberger C, Kanz L, and Bokemeyer C: Platinum organ toxicity and possible
prevention in patients with testicular cancer. Int J Cancer 83: 866-869, 1999.
11. Hartmann JT, Quietzsch D, Daikeler T, Kollmannsberger C, Mayer F, Kanz L, and Bokemeyer C: Mitomycin
C continuous infusion as salvage chemotherapy in pretreated patients with advanced gastric cancer.
Anticancer Drugs 10: 729-733, 1999.
12. Kollmannsberger C, Brugger W, Hartmann JT, Maurer F, Bohm P, Kanz L, and Bokemeyer C: Phase II
study of oral trofosfamide as palliative therapy in pretreated patients with metastatic soft-tissue sarcoma.
Anticancer Drugs 10: 453-456, 1999.
13. Kollmannsberger C, Pressler H, Mayer F, Kanz L, and Bokemeyer C: Cisplatinrefractory, HER2/neuexpressing germ-cell cancer: induction of remission by the monoclonal antibody Trastuzumab [letter]. Ann
Oncol 10: 1393-1394, 1999.
14. Kollmannsberger C, Hartmann JT, Kanz L, and Bokemeyer C: Therapy-related malignancies following
treatment of germ cell cancer. Int J Cancer 83: 860-863, 1999.
15. Pereira PL, Schick F, Einsele H, Farnsworth CT, Kollmannsberger C, Mattke A, Duda SH, and Claussen C:
MR-Tomographie von Knochenmarkveränderungen nach Hochdosis-Chemotherapie und autologer
peripherer Stammzell-Transplantation [MR tomography of the bone marrow changes after high-dosage
chemotherapy and autologous peripheral stem-cell transplantation]. Fortschr Röntgenstr 170: 251-257, 1999.
16. Kollmannsberger C, Gerl A, Schleucher N, Beyer J, Kuczyk M, Rick O, Casper J, Sosada M, Rie C, Kanz L,
and Bokemeyer C: Phase II study of bendamustine in patients with relapsed or cisplatin-refractory germ cell
cancer. Anticancer Drugs 11: 535-539, 2000.
17. Kollmannsberger C, Nichols C, Meisner C, Mayer F, Kanz L, and Bokemeyer C: Identification of prognostic
subgroups among patients with metastatic 'IGCCCG poorprognosis' germ-cell cancer: an explorative analysis
using cart modeling. Ann Oncol 11: 1115-1120, 2000.
18. Kollmannsberger C, Nichols C, Bamberg M, Hartmann JT, Schleucher N, Beyer J, Schoffski P, Derigs G,
Ruther U, Bohlke I, Schmoll HJ, Kanz L, and Bokemeyer C: First-line high-dose chemotherapy +/- radiation
therapy in patients with metastatic germ-cell cancer and brain metastases. Ann Oncol 11: 553-559, 2000.
*
19. Kollmannsberger C, Quietzsch D, Haag C, Lingenfelser T, Schroeder M, Hartmann JT, Baronius W, Hempel
V, Clemens M, Kanz L, and Bokemeyer C: A phase II study of paclitaxel, weekly, 24-hour continous infusion
5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer. Br J Cancer 83: 458-462,
2000.
20. Kollmannsberger C and Bokemeyer C: Therapy-related leukemia following high-dose chemotherapy:
Compensating for the benefit? Onkologie 320: 480-482, 2000.
21. Dittmann H, Soekler M, Kollmannsberger C, Dohmen BM, Baumann C, Kopp A, Bares R, Claussen C, Kanz
L, and Bokemeyer C: Comparison of 18FDG-PET with CT scans in the evaluation of patients with residual
and recurrent Hodgkin's lymphoma. Oncol Rep 8: 1393-1399, 2001.
22. Kuczyk M, Bokemeyer C, Hartmann JT, Schubach J, Walter C, Machtens S, Knuchel R, Kollmannsberger C,
Jonas U, and Serth J: Predictive value of altered p27Kip1 and p21WAF/Cip1 protein expression for the
clinical prognosis of patients with localized prostate cancer. Oncol Rep 8: 1401-1407, 2001.
23. Machtens S, Serth J, Bokemeyer C, Bathke W, Minssen A, Kollmannsberger C, Hartmann J, Knuchel R,
Kondo M, Jonas U, and Kuczyk M: Expression of the p53 and Maspin protein in primary prostate cancer:
correlation with clinical features. Int J Cancer 95: 337-342, 2001.
14
24. Bokemeyer C, Kollmannsberger C, Oechsle K, Dohmen BM, Pfannenberg A, Claussen C, Bares R, and
Kanz L: Early prediction of treatment response to high-dose salvage chemotherapy in patients with relapsed
germ cell cancer using [18F]-FDG PET. Br J Cancer 86: 506-511, 2002.
25. Honecker F, Kollmannsberger C, Quietzsch D, Haag C, Schroeder M, Spott C, Hartmann JT, Baronius W,
Hempel V, Kanz L, and Bokemeyer C: A phase II study of weekly paclitaxel, plus 24hour continuous infusion
5-fluorouracil, folinic acid and three weekly cisplatin for the treatment of patients with advanced gastric
cancer. Anticancer Drugs 13: 497-503, 2002.
*
26. Kollmannsberger C, Oechsle K, Dohmen BM, Pfannenberg A, Bares R, Claussen C, Kanz L, and
Bokemeyer C: Prospective comparison of [18F]-FDG PET with conventional assessment by CT scans and
serum tumor markers for the evaluation of residual masses in non-seminomatous germ cell cancer patients.
Cancer 94: 2353-2362, 2002.
27. Kollmannsberger C, Rick O, Derigs G, Schleucher N, Schoeffski P, Beyer J, Schoch R, Sayer H-G, Gerl A,
Kuczyk M, Spott C, Kanz L, and Bokemeyer C: Activity of oxaliplatin in patients with relapsed or cisplatinrefractory germ cell cancer: a study of the German Testicular Cancer Study Group (GTCSG). J Clin Oncol 20:
2031-2037, 2002.
*
28. Kollmannsberger C, Mayer F, Pressler H, Koch S, Kanz L, Oosterhuis JW, Looijenga LHJ, and Bokemeyer
C: Absence of c-KIT and members of the epidermal growth factor receptor family in refractory germ cell
cancer. Cancer 95: 301-308, 2002.
29. Kollmannsberger C, Rick O, Klapproth J, Sayer H-G, Hentrich M, Welslau M, Spott C, Kanz L, and
Bokemeyer C: Irinotecan in patients with relapsed or cisplatin refractory germ cell cancer: a phase II study of
the German Testicular Cancer Study Group. Br J Cancer 87: 729-732, 2002.
30. Kuczyk M, Machtens S, Bokemeyer C, Kollmannsberger C, Hartmann JT, Kondo M, Merseburger A, and
Jonas U: Surgical bladder preserving strategies in the treatment of muscle-invasive bladder cancer. World J
Urol 20: 183-189, 2002.
31. Kuczyk M, Munch T, Machtens S, Bokemeyer C, Wefer A, Hartmann J, Kollmannsberger C, Kondo M, and
Jonas U: The need for routine adrenalectomy during surgical treatment for renal cell cancer: the Hannover
experience. BJU Int 89: 517-522, 2002.
32. Kuczyk M, Munch T, Bokemeyer C, Merseburger A, Wefer A, Kollmannsberger C, Kondoh M, Wegener G,
Jonas U, Stenzl A: Is adrenalectomy an indispensable part of nephrectomy ? Results of a multivariate
statistical analysis. Urologe A 42: 366-373, 2003
33. Meyer F, Kollmannsberger C, Bokemeyer C: Absence of c-Kit and members of the epidermal
growth factor receptor famiily in refractory germ cell cancer [author reply]. Cancer 97: 1927-2928, 2003
34. Kollmannsberger C, Schleucher N, Rick O, Metzner B, Schoeffski P, Casper J, Sosada M, Schmoll HJ,
Bohlke I, Meisner C, Kanz L, and Bokemeyer C: Analysis of salvage treatments for germ cell cancer patients
who have relapsed after primary high-dose chemotherapy plus autologous stem cell support. Eur J Cancer
39: 775-782, 2003.
35. Bokemeyer C; Schleucher N; Metzner B; Thomas M; Rick O; Schmoll H-J; Kollmannsberger C; Boehlke I;
Kanz L; Hartmann J-T: First-line sequential high-dose VIP chemotherapy with autologous transplantation for
patients with primary mediastinal nonseminomatous germ cell tumours: a prospective trial. Br J Cancer 89:
29-35, 2003
36. Merseburger AS, Wegener G, Horstmann M, Oelke M, Zumbragel A, Bokemeyer C, Kollmannsberger C,
Jonas U, Stenzl A, Kuczyk M.: Impact of tumor size on long-term survival of patients with organ-confined
15
renal cell cancer Aktuelle Urol 34: 469-474, 2003
37. Kollmannsberger C; Bokemeyer C: Irinotecan in patients with relapsed or cisplatin-refractory germ cell
cancer: a phase II study of the German Testicular Cancer Study Group (authors reply). Br J Cancer 89: 11411142, 2003
38. Ott K; Sendler A; Becker K; Dittler H-J; Helmberger H; Busch R; Kollmannsberger C; Siewert J-R; Fink U:
Neoadjuvant chemotherapy with cisplatin, 5-FU, and leucovorin (PLF) in locally advanced gastric cancer: a
prospective phase II study. Gastric Cancer 6: 159-67, 2003
39. Schmoll, H. J., Kollmannsberger, C., Metzner, B., Hartmann, J. T., Schleucher,
Schleicher, J., Rick, O., Beyer, J., Hossfeld, D., Kanz, L., Berdel, W. E., Andreesen, R.,
Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin
autologous stem cell support for patients with advanced metastatic germ cell cancer: an
study of the German Testicular Cancer Study Group. J Clin Oncol, 21: 4083-4091, 2003.
N., Schoeffski, P.,
and Bokemeyer, C.
chemotherapy plus
extended phase I/II
*
40. Kollmannsberger, C., Beyer, J., Liersch, R., Schoeffski, P., Metzner, B., Rick, O., Hartmann, J. T., Stengele,
K., Hohloch, K., Spott, C., Kanz, L., and Bokemeyer, C. Combination chemotherapy with gemcitabine plus
oxaliplatin in patients with intensively pretreated or refractory germ cell cancer: a study of the German
Testicular Cancer Study Group. J Clin Oncol, 22: 108-114, 2004.
41. Pfannenberg, A. C., Oechsle, K., Kollmannsberger, C., Dohmen, B. M., Bokemeyer, C., Bares, R.,
Vontheim, R., and Claussen, C. D. [Early prediction of treatment response to high-dose chemotherapy in
patients with relapsed germ cell tumors using [18F]FDG-PET, CT or MRI, and tumor marker]. ROFOFortschritte auf dem Gebiet der Rontgenstrahlen und der Bildgebenden V, 176: 76-84, 2004.
42. Pfannenberg A. C., Oechsle K., Bokemeyer C., Kollmannsberger C., Dohmen B.M., Bares R., Hartmann
J.T., Vonthein R., Claussen C.D. The role of [(18)F] FDG-PET, CT/MRI and tumor marker kinetics in the
evaluation of postchemotherapy residual masses in metastatic germ cell tumors-prospects for management.
World J Urol., 22:132-139, 2004
43. Kuczyk M., Bokemeyer C., Kollmannsberger C., Corvin S., Anastasiadis A., Machtens S., Merseburger A.,
Wegener G., Stenzl A., Hartmann J., Jonas U. Late relapse after treatment for nonseminomatous testicular
germ cell tumors according to a single center-based experience. World J Urol, 22:55-59, 2004
44. Bokemeyer C., Kollmannsberger C., Stenning S., Hartmann J.T., Horwich A., Clemm C., Gerl A., Meisner
C., Rueckerl C.P., Schmoll H.J., Kanz L., Oliver T.: Metastatic seminoma treated with either single agent
carboplatin or cisplatin based combination chemotherapy: a pooled analysis of two randomized trials. Br J
Cancer, 91:683-687, 2004.
45. Schmoll H.J., Souchon R., Krege S., Albers P., Beyer J., Kollmannsberger C., Fossa S.D., Skakkebaek
N.E., de Wit R., Fizazi K., Droz J.P., Pizzocaro G., Daugaard G., de Mulder P.H., Horwich A., Oliver T.,
Huddart R., Rosti G., Paz Ares L., Pont O., Hartmann J.T., Aass N., Algaba F., Bamberg M., Bodrogi I.,
Bokemeyer C., Classen J., Clemm S., Culine S., de Wit M., Derigs H.G., Dieckmann K.P., Flasshove M.,
Garcia del Muro X., Gerl A., Germa-Lluch J.R., Hartmann M., Heidenreich A., Hoeltl W., Joffe J., Jones W.,
Kaiser G., Klepp O., Kliesch S., Kisbenedek L., Koehrmann K.U., Kuczyk M., Laguna M.P., Leiva O., Loy V.,
Mason M.D., Mead G.M., Mueller R.P., Nicolai N., Oosterhof G.O., Pottek T., Rick O., Schmidberger H.,
Sedlmayer F., Siegert W., Studer U., Tjulandin S., von der Maase H., Walz P., Weinknecht S., Weissbach L.,
Winter E., Wittekind C.; European Germ Cell Cancer Consensus Group. European consensus on diagnosis
and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG).
Ann Oncol. 16:172-173, 2005.
46. Wierecky J., Kollmannsberger C., Boehlke I., Kuczyk M., Schleicher J., Schleucher N., Metzner B., Kanz L.,
Hartmann JT., Bokemeyer C.: Secondary leukemia after first-line high-dose chemotherapy for patients with
advanced germ cell cancer. J Cancer Res Clin Oncol 131: 255-260, 2005
16
47. Dalal B.I., Kollmannsberger C.: Drug-induced haemolysis and methaemoglobinaemia in glucose 6phosphate dehydrogenase deficiency. Br J Haematol. 129:291, 2005
48. Kollmannsberger C., Budach W., Stahl M., Schleucher N., Hehr T., Wilke H., Schleicher J., Vanhoefer U.,
Jehle E.C., Oechsle K., Trarbach T., Boehlke I., Kanz L., Hartmann JT., Bokemeyer C.: Adjuvant
chemoradiation using 5-fluorouracil/folinic acid/cisplatin with or without paclitaxel and radiation in patients with
completely resected high-risk gastric cancer: two cooperative phase II studies of the AIO/ARO/ACO. Ann
Oncol. 16:1326-33, 2005.
49. Al-Tourah AJ, Murray N, Coppin C, Kollmannsberger C, Man A, Chi KN.: Minimizing treatment without
compromising cure with primary surveillance for clinical stage I embryonal predominant nonseminomatous
testicular cancer: a population based analysis from British Columbia. J Urol. 174: 2209-13, 2005
50. Michels J., Montemurro T., Murray N., Kollmannsberger C., Nguyen K. Chi.: First- and second-line
chemotherapy with docetaxel or mitoxantrone in patients with hormone-refractory prostate cancer: does
sequence matter? Cancer. 106: 1041-1046, 2006
51. Kollmannsberger C., Nichols C., Bokemeyer C.: Recent advances in the management of patients with
platinum-refractory germ cell tumors. Cancer 106:1217–26, 2006
52. McArthur HL., Dalal BI., Kollmannsberger C.: Intravascular hemolysis as a complication of clostridium
perfringens sepsis. J Clin Oncol. 24: 2387-2388, 2006.
53. Kollmannsberger C., Schittenhelm M., Honecker F., Tillner J, Weber D., Oechsle K., Kanz L., Bokemeyer
C.: A Phase I Study of the Humanized Monoclonal Anti–Epidermal Growth Factor Receptor (EGFR) Antibody
EMD 72000 (Matuzumab) in Combination with Paclitaxel in Patients with EGFR-Positive Advanced Non–
Small Cell Lung Cancer (NSCLC). Ann Oncol 17:1007-1013, 2006
54. Oechsle K, Honecker F, Kollmannsberger C, Rick O, Grunwald V, Mayer F, Hartmann JT, Bokemeyer C.:
An open-label, multicenter phase II trial of capecitabine in patients with cisplatin-refractory or relapsed germ
cell tumors. Anticancer Drugs. 18(3):273-6, 2007
55. Knox JJ, Hotte SJ, Kollmannsberger C, Winquist E, Fisher B, Eisenhauer EA.: Phase II study of Triapine in
patients with metastatic renal cell carcinoma: a trial of the National Cancer Institute of Canada Clinical Trials
Group (NCIC IND.161). Invest New Drugs. 2007 Mar 28; [Epub ahead of print]
56. Kollmannsberger C., Soulieres D., Wong R., Scalera A., Gaspo R., Bjarnason G.: Sunitinib in metastatic
renal cell carcinoma: Recommendations for management of side-effects. CUAJ 1 (Suppl.2): 41-54, 2007
57. Lorch A, Kollmannsberger C, Hartmann JT, Metzner B, Schmidt-Wolf IG, Berdel WE, Weissinger F,
Schleicher J, Egerer G, Haas A, Schirren R, Beyer J, Bokemeyer C, Rick O; German Testicular Cancer Study
Group. Single versus sequential high-dose chemotherapy in patients with relapsed or refractory germ cell
tumors: a prospective randomized multicenter trial of the German Testicular Cancer Study Group. J Clin
Oncol 25: 2778-84, 2007.
58. Welz S, Hehr T, Kollmannsberger C, Bokemeyer C, Belka C, Budach W.: Renal toxicity of adjuvant
chemoradiotherapy with cisplatin in gastric cancer. Int J Radiat Oncol Biol Phys. 69:1429-35, 2007.
59. Robinson A, Bainbridge T, Kollmannsberger C.: A spermatocytic seminoma with rhabdomyosarcoma
transformation and extensive metastases. Am J Clin Oncol. 30: 440-441, 2007.
60. Bokemeyer C, Oechsle K, Honecker F, Mayer F, Hartmann JT, Waller CF, Böhlke I, Kollmannsberger C.:
Combination chemotherapy with gemcitabine, oxaliplatin, and paclitaxel in patients with cisplatin-refractory or
multiply relapsed germ-cell tumors: a study of the German Testicular Cancer Study Group. Ann Oncol. 19:
17
448-53, 2008
61. Krege S, Beyer J, Souchon R, Albers P, Albrecht W, Algaba F, Bamberg M, Bodrogi I, Bokemeyer C,
Cavallin-Ståhl E, Classen J, Clemm C, Cohn-Cedermark G, Culine S, Daugaard G, De Mulder PH, De Santis
M, de Wit M, de Wit R, Derigs HG, Dieckmann KP, Dieing A, Droz JP, Fenner M, Fizazi K, Flechon A, Fosså
SD, Garcia Del Muro X, Gauler T, Geczi L, Gerl A, Germa-Lluch JR, Gillessen S, Hartmann JT, Hartmann M,
Heidenreich A, Hoeltl W, Horwich A, Huddart R, Jewett M, Joffe J, Jones WG, Kisbenedek L, Klepp O,
Kliesch S, Koehrmann KU, Kollmannsberger C, Kuczyk M, Laguna P, Leiva Galvis O, Loy V, Mason MD,
Mead GM, Mueller R, Nichols C, Nicolai N, Oliver T, Ondrus D, Oosterhof GO, Paz-Ares L, Pizzocaro G, Pont
J, Pottek T, Powles T, Rick O, Rosti G, Salvioni R, Scheiderbauer J, Schmelz HU, Schmidberger H, Schmoll
HJ, Schrader M, Sedlmayer F, Skakkebaek NE, Sohaib A, Tjulandin S, Warde P, Weinknecht S, Weissbach
L, Wittekind C, Winter E, Wood L, von der Maase H.: European Consensus Conference on Diagnosis and
Treatment of Germ Cell Cancer: A Report of the Second Meeting of the European Germ Cell Cancer
Consensus group (EGCCCG): Part I. Eur Urol. 53: 478-96, 2008.
62. Krege S, Beyer J, Souchon R, Albers P, Albrecht W, Algaba F, Bamberg M, Bodrogi I, Bokemeyer C,
Cavallin-Ståhl E, Classen J, Clemm C, Cohn-Cedermark G, Culine S, Daugaard G, De Mulder PH, De Santis
M, de Wit M, de Wit R, Derigs HG, Dieckmann KP, Dieing A, Droz JP, Fenner M, Fizazi K, Flechon A, Fosså
SD, Garcia Del Muro X, Gauler T, Geczi L, Gerl A, Germa-Lluch JR, Gillessen S, Hartmann JT, Hartmann M,
Heidenreich A, Hoeltl W, Horwich A, Huddart R, Jewett M, Joffe J, Jones WG, Kisbenedek L, Klepp O,
Kliesch S, Koehrmann KU, Kollmannsberger C, Kuczyk M, Laguna P, Leiva Galvis O, Loy V, Mason MD,
Mead GM, Mueller R, Nichols C, Nicolai N, Oliver T, Ondrus D, Oosterhof GO, Paz-Ares L, Pizzocaro G, Pont
J, Pottek T, Powles T, Rick O, Rosti G, Salvioni R, Scheiderbauer J, Schmelz HU, Schmidberger H, Schmoll
HJ, Schrader M, Sedlmayer F, Skakkebaek NE, Sohaib A, Tjulandin S, Warde P, Weinknecht S, Weissbach
L, Wittekind C, Winter E, Wood L, von der Maase H.: European Consensus Conference on Diagnosis and
Treatment of Germ Cell Cancer: A Report of the Second Meeting of the European Germ Cell Cancer
Consensus group (EGCCCG): Part II. Eur Urol. 53: 497-513, 2008
63. Oechsle K, Kollmannsberger C, Honecker F, Boehlke I, Bokemeyer C: Cerebral metastases in
nonseminomatous germ cell tumor patients undergoing primary high dose chemotherapy. Eur J Cancer :
44:1663-1669, 2008
64. Jewett MA, Knox JJ, Kollmannsberger C, Basiuk J.: Canadian kidney cancer forum 2008. Can Urol Assoc J.
2(3):183, 2008.
65. Chi KN, Siu LL, Hirte H, Hotte SJ, Knox J, Kollmannsberger C, Gleave M, Guns E, Powers J, Walsh W, Tu
D, Eisenhauer E.: A phase I study of OGX-011, a 2'-methoxyethyl phosphorothioate antisense to clusterin, in
combination with docetaxel in patients with advanced cancer. Clin Cancer Res. 14(3):833-839, 2008.
66. C. Kollmannsberger, F. Honecker, C. Bokemeyer: Pharmacotherapy of relapsed metastatic testicular
cancer. Expert Op Pharmacother. 9:2259-2272, 2008
67. C. Kollmannsberger, C. Bokemeyer: Salvage chemotherapy after failure of first-line chemotherapy in
patients with metastatic testicular cancer. Curr Opin Support Palliat Care, 2:167-172, 2008
68. Oechsle K, Bokemeyer C, Hartmann JT, Budach W, Trarbach T, Stahl M, Boehlke I, Kollmannsberger C.:
Four consecutive multicenter phase II trials of adjuvant chemoradiation in patients with completely resected
high-risk gastric cancer: the experience of the German AIO/ARO/CAO group. J Cancer Res Clin Oncol.
135:163-72, 2009
69. Heng DY, Chi KN, Murray N, Jin T, Garcia JA, Bukowski RM, Rini BI, Kollmannsberger C.: A populationbased study evaluating the impact of sunitinib on overall survival in the treatment of patients with metastatic
renal cell cancer. Cancer. 115(4):776-783, 2009.
70. Schittenhelm M, Kollmannsberger C, Oechsle K, Harlow A, Town A, Honecker F, Weber D, Tillner J,
Störkel S, Corless C, Wong K, Bokemeyer C, Heinrich M: Molecular determinants of response to Anti-EGFR
18
Matuzumab in combination with paclitaxel in patients with advanced non-small cell lung cancer. Molecular
Cancer Therapeutics, e-pub anhead of print
71. Nichols CR, Kollmannsberger C: “Vox Populi: Using Community-Based Studies to Determine Best
Management of Early-Stage Nonseminoma”. J Clin Oncol 2009” e-pub ahead of print
72.
(b) Conference Proceedings
(c) Other
Abstracts (first author only)
1. Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer. (Poster) Annual
Meeting of the German Society of Hematology/Oncology, Linz, 1997.
2. "FDG-PET for the evaluation of high-dose chemotherapy (HD-CTX) in patients with metastatic germ cell
tumors (GCT)." (Oral presentation) 23rd Congress of the European Society of Medical Oncology, Athens
Greece, 1998.
3. "A phase II trial of paclitaxel, cisplatin, and weekly 24h infusion of 5-fluorouracil (5-FU) / folinic acid in patients
(pts) with advanced gastric cancer." (Poster) 23rd Congress of the European Society of Medical Oncology,
Athens Greece, 1998.
4. "Secondary acute myeloid leukemia (S-AML) or myelodysplastic syndrome (S-MDS) following high-dose
etoposide (>/= 2 g/m) containing chemotherapy in 302 patients with germ cell tumors (GCT)." (Poster) 34th
Annual Meeting of the American Society of Clinical Oncology, Los Angeles USA, 1998.
5. First-line high-dose chemotherapy (HD-CT) +/- radiation therapy (RTX) in patients (pts) with CNS metatstases
of non-seminomatous germ cell tumors (GCT). (Poster) 35th Annual Meeting of the American Society of
Clinical Oncology, Atlanta USA, 1999.
6. "First-line high-dose chemotherapy with autologous stem cell transplantation versus standard-PEB/PEI for
patients with poor prognosis germ cell cancer.". (Oral presentation) Annual Meeting of the German Society
of Hematology/Oncology, Jena, 1999.
7. "Reduction of skin toxicity of pegylated liposomal doxorubicin (PLD) by concomitant administration of
dexamethasone (DEX) and pyridoxin (PYR) in patients (pts) with antracycline-sensitive malignancies - a
phase I/II trial.". (Poster) 25th Congress of the European Society of Medical Oncology, Hamburg, 2000.
8. A phase II study of paclitaxel, weekly 24-hour continuous infusion (CI) of 5-fluorouracil / folinic acid (FA) and
cisplatin in patients (pts) with advanced gastric cancer. (Poster) 36th Annual Meeting of the American Society
of Clinical Oncology, New Orleans USA, 2000.
9. "[18F]-fluorodeoxyglucose (FDG) positron emission tomography (PET) for the early prediction of response to
high-dose chemotherapy (HD-CT) in patients (pts) with metastatic germ cell cancer.". (Poster) Annual
Meeting of the German Society of Hematology/Oncology, Graz, 2000.
19
10. "Oxaliplatin in patients (pts) with cisplatin-refractory germ cell cancer (GCT).". (Poster) 37th Annual Meeting
of the American Society of Clinical Oncology, San Francisco USA, 2001.
11. "Lack of overexpression of the EGF receptor family in refractory germ cell cancer (GCT).". (Oral
presentation) Annual Meeting of the German Society of Hematology/Oncology, Mannheim, 2001
12. "Oxaliplatin (OX) in patients (pts) with relapsed or cisplatin refractory germ cell cancer (GCT). Final results of
a German Testicular Cancer Study Group investigation.". (Oral presentation) Annual Meeting of the German
Society of Hematology/Oncology, Mannheim, 2001.
13. Outcome of patients (pts) with "poor prognosis" germ cell cancer (GCT) relapsing after primary high-dose
chemotherapy plus stem cell support (pHD/PBSCT). (Poster) 38th Annual Meeting of the American Society of
Clinical Oncology, Orlando USA, 2002.
14. Epidermal growth factor receptor (EGFR) antibody EMD 72000 in combination with paclitaxel (P) in patients
(pts) with EGFR-positive advanced non-small cell lung cancer (NSCLC): A phase-I study. (Poster
discussion) 39th Annual Meeting of the American Society of Clinical Oncology, Chicago 2003
15. Adjuvant radiochemotherapy using 5-FU/Folinic acid/cisplatin  Paclitaxel and radiation in patients with
completely (R0) resected high-risk gastric cancer (UICC stages II-IV (M0): A phase II study of the
AIO/ARO/ACO. (Oral presentation) Annual Meeting of the German Society of Hematology/Oncology, Basel,
2003.
16. Treatment of patients with relapsed of cisplatin-refractory germ cell cancer with a combination of gemcitabine
and oxaliplatin: A phase II study of the German Testicular Cancer Study Group. (Oral presentation) Annual
Meeting of the German Society of Hematology/Oncology, Basel, 2003.
17. Single agent carboplatin versus cisplatin based combination chemotherapy in patients with advanced
seminoma: a meta-analysis of two European randomized trials. (Oral presentation) Annual Meeting of the
German Society of Hematology/Oncology, Basel, 2003.
18. Gonadal late effects, fertility and sexual functioning in long-term survivors after high-dose chemotherapy with
autologous stem cell transplantation (HD-CT) for testicular cancer. (Poster discussion) Annual meeting of
the American Society of Clinical Oncology, New Orleans, 2004
19. A population-based study evaluating metastatic renal cell cancer (mRCC) patients treated with interferon
(IFN) alone, first-line IFN then second-line sunitinib, or sunitinib alone. Annual Meeting of the American
Society of Clinical Oncology, Chicago 2007
20. Phase I study of daily administration of MGCD265 to patients with advanced malignancies (Study 265-101),
Annual Meeting of the American Society of Clinical Oncology, Orlando 2009
Presentations
See above
02. Non Refereed Publications
(a) Journals
1. Bokemeyer C, Kollmannsberger C, and Kanz L: The potential role of topotecan in the treatment of pediatric
and adult soft-tissue sarcomas. Onkologie 21 (Suppl. 4): 124-127, 1998.
20
2. Jakob A, Kollmannsberger C, Kanz L, and Bokemeyer C: Spattoxizitat nach Chemotherapie maligner
Hodentumoren. [Late toxicity after chemotherapy of malignant testicular tumors]. Urologe A 37: 635-647,
1998.
3. Bokemeyer C and Kollmannsberger C: UICC Symposium on Testicular Cancer, Tübingen 19./20 März 1999
(Kongreßbericht). Onkologie 22: 34-35, 1999.
4. Hartmann JT, Kuczyk MA, Kollmannsberger C, Kanz L, and Bokemeyer C: Future prospects in the
chemotherapy of metastatic nonseminomatous testicular germ-cell cancer. World J Urol 17: 324-333, 1999.
5. Kollmannsberger C, Mross K, Jakob A, Kanz L, and Bokemeyer C: Topotecan – A novel topoisomerase I
inhibitor: pharmacology and clinical experience. Oncology 56: 1-12, 1999.
6. Kollmannsberger C, Kuzcyk M, Mayer F, Hartmann JT, Kanz L, and Bokemeyer C: Late toxicity following
curative treatment of testicular cancer. Semin Surg Oncol 17: 275-281, 1999.
7. Kollmannsberger C and Bokemeyer C: Behandlung des metastasierten Nierenzellkarzinoms (Journal Club).
Onkologe 5: 824-825, 1999.
8. Barth-Kollmer C, Kollmannsberger C, and Bokemeyer C: Pamidronat zur Prävention osseärer Ereignisse
(Journal Club). Onkologe 6: 587-589, 2000.
9. Bokemeyer C, Kollmannsberger C, Hartmann JT, and Kanz L: Follow up after primary treatment: curable
diseases treated non-surgically. Ann Oncol 11 Suppl 373-8: 8, 2000.
10. Bokemeyer C, Kollmannsberger C, Oettle H, and Kanz L: Aktuelle Aspekte zur Chemotherapie von
metastasierten Pankreas- und Gallenwegskarzinomen. [Current aspects of chemotherapy of metastatic
pancreatic and biliary tract carcinomas]. Schweiz Rundsch Med Prax 89: 1545-1552, 2000.
11. Kollmannsberger C, Mayer F, Kuczyk M, Kanz L, and Bokemeyer C: Treatment of patients with metastatic
germ cell tumors relapsing after high-dose chemotherapy. World J Urol 19: 120-125, 2001.
12. Kollmannsberger C and Bokemeyer C: Chemotherapie des metastasierten Blasenkarzinoms (Journal Club).
Onkologe 7: 580-581, 2001.
13. Kollmannsberger
C
and
Bokemeyer
C:
Adjuvante
Chemotherapie
bei
Hochrisikoweichteilsarkomen der Extremitäten (Journal Club). Onkologe 7: 906-907, 2001.
Patienten
mit
14. Bokemeyer C, Hartmann JT, Kuczyk M, Truss MC, Kollmannsberger C, Beyer J, Jonas U, and Kanz L:
Recent strategies for the use of paclitaxel in the treatment of urological malignancies. World J Urol 16: 155162, 2002.
15. Kollmannsberger C, Albers P, and Bokemeyer C: Chemotherapie des metastasierten Blasenkarzinoms
[Chemotherapy of metastatic bladder cancer]. Onkologe 9: 950-961, 2002.
16. Kollmannsberger C, Budach W, and Bokemeyer C: Adjuvante Radiochemotherapie bei Patienten mit
Hochrisikomagenkarzinom (Journal Club). Onkologe 8: 392-394, 2002.
17. Kollmannsberger C and Bokemeyer C: PEB ist nicht gleich PEB (Journal Club). Onkologe 8: 191-192, 2002.
18. Kollmannsberger C., Bokemeyer C.: Treatment of patients with good prognosis germ cell cancer. Onkologe
9: 980-984, 2003
19. Rick O, Kollmannsberger C, Hartmann JT, Braun T, Siegert W, Bokemeyer C, Beyer J.: The role of highdose chemotherapy in relapsed germ cell tumors. World J Urol. 22: 25-32, 2004
21
20. Kollmannsberger C., Gerber E., Budach W., Bokemeyer C.: Rolle der systemischen Therapie ±
Radiotherapie beim resektablen Kardia-/Magenkarzinom [ Role of systemic treatment ± radiation in resectable
cardia-/gastric adenocarcinoma]. Onkologe 11: 650-657, 2005
21. Kollmannsberger C, Honecker F, Bokemeyer C.: Treatment of germ cell tumors—update 2006. Ann Oncol
17 Suppl 10:x31-5, 2006
(b) Conference Proceedings
Kollmannsberger C., Honecker F., Bokemeyer C.: Treatment of germ cell tumors – update 2006. ESMO
Educational Book 2006
(c) Other
03. Books
(a) Authored
(b) Edited
(c) Chapters
1. Kollmannsberger C and Fink U: Pankreaskarzinom [Pancreatic cancer]. In: Seeber S und Schütte J (Hrsg.):
Therapiekonzepte Onkologie 3.Auflage. Springer-Verlag, Berlin, Heidelberg, New York 621-639, 1998
2. Bokemeyer C, Kollmannsberger C, Weiß J, and Schmoll H-J: Gonadale Toxizität und Infertilität [Gonadal
toxicity and infertility]. In: Schmoll H-J, Hoeffken K, und Possinger K (Hrsg.): Kompendium Internistische
Onkologie 2.Auflage. Springer-Verlag, Heidelberg - New York 1427-1440, 1999
3. Bokemeyer C, Kollmannsberger C, Weiß J, and Schmoll H-J: Teratogenität und Mutagenität [Teratogenicity
and mutagenesis]. In: Schmoll H-J, Hoeffken K, und Possinger K (Hrsg.): Kompendium Internistische
Onkologie 2.Auflage. Springer-Verlag, Heidelberg-New York 1441-1446, 1999
4. Bokemeyer C and Kollmannsberger C: Secondary malignancies. In: Lipp H-P (Hrsg.): Anticancer Drug
Toxicity. Marcel Dekker Inc., New York 525-548, 1999
5. Bokemeyer C, Kollmannsberger C, Hartmann JT, and Kanz L: Einsatz von Paclitaxel in der Behandlung von
malignen Keimzelltumoren des Hodens und von Urothelkarzinomen [Paclitaxel in the treatment of urological
malignancies]. In: Hoeffken K, du Bois A, Kuehnle H, und Bokemeyer C (Hrsg.): Aktuelle Onkologie 102:
Taxol-neue Daten zur Therapie solider Tumoren. Zuckschwerdt Verlag, München 90-102, 1999
6. Bokemeyer C, Hartmann JT, Kollmannsberger C, and Kanz L: Neue Entwicklungen in der Therapie
urogenitaler Malignome [New developments in the treatment of urological malignancies]. In: du Bois A,
Bokemeyer C, Gatzemeier U, Kreienberg R, und Kuehnle H (Hrsg.): Aktuelle Onkologie 107: Mit Taxol in der
Therapie solider Tumoren ins nächste Jahrtausend. Zuckschwerdt Verlag, München 132-145, 1999
7. Bokemeyer C, Kollmannsberger C, Hartmann JT, Honecker F, Mayer F, and Kanz L: Aktuelle Entwicklungen
in der Chemotherapie des Urothelkarzinoms [New developments in the chemotherapy of urothelial cancer].
22
In: du Bois A, Bokemeyer C, Gatzemeier U, und Lück H-J (Hrsg.): Aktuelle Onkologie 111: Taxol - Aktuelle
Aspekte in der Therapie solider Tumoren. Zuckschwerdt Verlag, München 87-95, 2001
8. Kollmannsberger C, Quietzsch D, Kanz L, and Bokemeyer C: Neue Entwicklungen in der Chemotherapie
des Magenkarzinoms [New developments in the treatment of gastric cancer]. In: du Bois A, Bokemeyer C,
Gatzemeier U, und Lück H-J (Hrsg.): Aktuelle Onkologie 111: Taxol - Aktuelle Aspekte in der Therapie solider
Tumoren. Zuckschwerdt Verlag, München 96-105, 2001
9. Mitautor für: In: Deutsche Gesellschaft für Hämatologie und Onkologie (Hrsg.): Therapie-Empfehlungen der
internistischen Onkologie – Solide Tumoren. Zuckschwerdt Verlag, München 2001
10. Bokemeyer C and Kollmannsberger C: Maligne Keimzelltumoren des Mannes [Malignant germ cell tumors].
In: Berdel/Böhm/Classen/Diehl/Kochsiek/Schmiegel (Hrsg.): Innere Medizin 5.Auflage. Urban & Fischer
Verlag, München, 2003
11. Kollmannsberger C and Fink U: Pankreaskarzinom [Pancreatic cancer]. In: Seeber S und Schütte J (Hrsg.):
Therapiekonzepte Onkologie 4.Auflage. Springer-Verlag, Berlin, Heidelberg, New York. 2003
12. Kollmannsberger C and Bokemeyer C: Gonadotoxizitaet after chemotherapy [Gonadal toxicity after
chemotherapy]. In: Link H., Bokemeyer C., Feyer A.: Supportivtherapie, Deutscher Ärzte-Verlag GmbH,
Koeln, 2004
13. Bokemeyer C, Kollmannsberger C: Secondary malignancies. Kompendium Internistische Onkologie.
Springer-Verlag Heidelberg, Berlin, New York, 2006
04. Patents
05. Special Copyrights
06. Artistic Works, Performances, Designs
07. Other Works
08. Work Submitted
09. Work In Progress
Management of Disseminated Non-seminomatous Germ Cell Tumors with Risk-Based Chemotherapy followed by
Response Guided Post-Chemotherapy Surgery – Cooperation with Health Science University, Oregon.
Surveillance as primary treatment strategy for stage I nonseminoma patients – Cooperation with Health Science
University, Oregon
Outcome of stage I seminoma patients treated with active surveillance – Cooperation with Health Science
University, Oregon
Prognostic factors in stage I nonseminoma – Cooperation with Erasmus University Rotterdam, The Netherlands
Sunitinib as palliative treatment for cisplatin-refractory germ cell cancer – a phase II study
ABT-869 as salvage treatment for patients with metastatic RCC and failure of first line sunitinib therapy – a phase
II study
23
Outcome of patients with curatively resected gastric and GE junction tumors in BC – retrospective review of BC
patients
Local principal investigator in several phase I, II and III studies
24